IBI352g4a
IBI352g4a is a humanized IgG1 monoclonal antibody targeting PVRIG (Kd = 0.53 nM) and acts as a PVRIG/PVRL2 inhibitor. The anti-tumor effect of IBI352g4a depends on the binding of its Fc region to FcγR. IBI352g4a binds to the extracellular domains of human and cynomolgus monkey PVRIG, and blocks the PVRIG-PVRL2 interaction. IBI352g4a induces NK cell activation, promotes their degranulation and tumor killing. IBI352g4a can be used in the research of gastric cancer.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Human
IBI352g4a binds recombinant human PVRIG with high affinity, with a Kd of 0.53 nM[1].
IBI352g4a binds recombinant cynomolgus monkey PVRIG with a Kd of 2.71 nM[1].
IBI352g4a binds human PVRIG-overexpressing GS-CHO cells in a dose-dependent manner, with an EC50 of 2.03 nM[1].
IBI352g4a binds cynomolgus monkey PVRIG-overexpressing GS-CHO cells in a dose-dependent manner, with an EC50 of 7.42 nM[1].
IBI352g4a completely blocks the interaction between human PVRIG and PVRL2, with an IC50 of 0.94 nM[1].
IBI352g4a (10 μg/mL; 4 h) significantly increases degranulation (CD107a expression) in purified human NK cells cocultured with K562 cells for 4 h[1].
IBI352g4a (10 μg/mL; 16 h) significantly increases activation (CD137 expression) in purified human NK cells cocultured with K562 cells for 16 h[1].
IBI352g4a (10 μg/mL; 5 h) significantly increases NK cell-mediated killing of CTV-labeled K562 cells[1].
IBI352g4a (10 ng/mL-10 μg/mL; 4 h) induces dose-dependent NK cell-mediated killing of K562 cells, with an EC50 of 0.075 nM after 4 h of coculture[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:purified human NK cells, CellTrace Violet (CTV)-labeled K562 tumor cells
-
Concentration:10 μg/mL
-
Incubation Time:5 h
-
Result:Significantly increased the percentage of PI+ CTV+ dead K562 cells compared to control IgG treatment.
-
Cell Line:NK cells, K562 cells
-
Concentration:10-8, 10-6, 10-4, 10-2, 100, 102 μg/mL
-
Incubation Time:4 h
-
Result:Induced dose-dependent NK cell-mediated killing of K562 cells, with an EC50 of 0.075 nM after 4 h of coculture.
IBI352g4a (10 mg/kg; i.p.; 6 doses on days 5-22) has limited antitumor efficacy against human gastric cancer in T-cell-only reconstituted NOG mice, indicating NK cells are critical for its optimal activity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:B-NDG hIL15 mice[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; 6 doses on days 7, 10, 13, 17, 20, 24
-
Result:Reduced mean tumor volume.
Maintained stable body weight throughout treatment.
-
Animal Model:NOG mice[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; 6 doses on days 5, 8, 11, 15, 18, 22
-
Result:Showed limited antitumor efficacy, with significantly weaker activity compared to its efficacy in B-NDG hIL15 mice with NK and T cell reconstitution.
PVRIG/CD112R
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
IBI352g4a Related Classifications
HY-P992381 Related Classifications
Powered by Bioz